More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $125.97 |
|
|||
| Open | $126.72 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $131.58 | ||||
| Day Low | $126.46 | ||||
| P/E | 72.52 | ||||
| EPS | $1.81 | ||||
| Volume | 8,091,211 | ||||
- Form 4 GILEAD SCIENCES, INC. For: Jul 01 Filed by: O'Day Daniel Patrick
- FDA clears Gilead's Trodelvy for first-line metastatic TNBC
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- EU approves Gilead's Trodelvy for first-line metastatic TNBC
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald: Yeztugo Total TRx Down
- Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald post CFO Chat
- Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Mercier Johanna
- Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Dickinson Andrew D
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
